Rutgers Cancer Institute of New Jersey ( Site 1008) is a clinical research site located in New Brunswick, New Jersey, United States 08903.
Crixeo Health Trust Score: 58/100 (POOR). This profile has not yet been claimed by the site owner.
Rutgers Cancer Institute of New Jersey ( Site 1008) has participated in 1 clinical trials with 1 currently active.
Therapeutic areas: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma.
Sponsors: Merck Sharp & Dohme LLC.
Trust Score: 58/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
Rutgers Cancer Institute of New Jersey ( Site 1008) has a Crixeo Trust Score of 58/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Rutgers Cancer Institute of New Jersey ( Site 1008) has 1 clinical trials on record, with 1 currently active. Their work covers B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma.
Rutgers Cancer Institute of New Jersey ( Site 1008) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.